To study the effect and mechanism of dihydrochromone-spliced polycyclic pyrrole-spiroepoxidole compound 3m on cutaneous squamous cell carcinoma.
METHODS
2
Using human cutaneous squamous cell carcinoma A431 and Colo-16 cells as research subjects, CCK-8 assay was used to detect the effects of different concentrations of 3m (5, 10, 20, 40, 80 μmol/L) on the proliferation of A431 and Colo-16 cells after 24, 48 and 72 hours; the median inhibitory concentration (IC
50
) was calculated at 48 h of treatment. A431 and Colo-16 cells were divided into control group, 3m low-concentration and high-concentration groups (15, 30 μmol/L). After treated with relevant drugs or culture medium for 48 h, the morphological changes of cells in each group were observed by inverted microscope. Clone formation rate, migration rate and number of cell invasions, cell cycle distribution and apoptosis rate were detected. The phosphorylation, or expression of Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway related proteins [JAK2, STAT3, B-cell lymphocyte-2 (Bcl-2), Bcl-2-associated X protein (Bax)], and their mRNA expression in cells were detected.
RESULTS
2
3m could significantly inhibit the proliferation of A431 and Colo-16 cells after treated for 24, 48, 72 h (
P
<0.01), and IC
50
of them were 20.36, 23.72 μmol/L, respectively. After 48 hours of treatment, compared with control group, A431 and Colo-16 cells arranged sparsely and loosely connected in 3m low-concentration and high-concentration groups. The clone formation rate, migration rate, number of cell invasions, mRNA expressions of JAK2,STAT3 and Bcl-2, the phosphorylation of JAK2 and STAT3, protein expression of Bcl-2 were significantly decreased/weakened (
P
<0.01). Proportion of cell cycle in G2 phase, apoptosis rate, protein and mRNA expression of Bax were increased significantly (
P
<0.01); and all the above effects were in dose-dependent manner.
CONCLUSIONS
2
3m can inhibit the proliferation, clone formation, migration and invasion abilities of cutaneous squamous cell carcinoma A431 and Colo-16 cells in a dose-dependent manner, the mechanism of which may be associated with inhibiting the activity of JAK2/STAT3 signaling pathway, and inducing cell apoptosis.
CORCHADO-COBOS R,GARCÍA-SANCHA N,GONZÁLEZ-SARMIENTO R,et al. Cutaneous squamous cell carcinoma:from biology to therapy[J]. Int J Mol Sci,2020,21(8):2956.
FIRNHABER J M. Basal cell and cutaneous squamous cell carcinomas:diagnosis and treatment[J]. Am Fam Physician,2020,102(6):339-346.
FARBERG A S,FITZGERALD A L,IBRAHIM S F,et al. Current methods and caveats to risk factor assessment in cutaneous squamous cell carcinoma (cSCC):a narrative review[J]. Dermatol Ther (Heidelb),2022,12(2):267-284.
STRATIGOS A J,GARBE C,DESSINIOTI C,et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin:part 1. epidemiology,diagnostics and prevention[J]. Eur J Cancer,2020,128:60-82.
DROLL S,BAO X M. Oh,the mutations you’ll acquire! A systematic overview of cutaneous squamous cell carcinoma[J]. Cell Physiol Biochem,2021,55(S2):89-119.
CLAVEAU J,ARCHAMBAULT J,ERNST D S,et al. Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma[J]. Curr Oncol,2020,27(4):e399-e407.
CHEN S,JING Y,LIU X L,et al. One-pot multicomponent construction of chromanone-fused pyrrolidinyl spirooxindole collections through a decarboxylative 1,3-dipolar[3 + 2]cycloaddition reaction[J]. Synth Commun,2019,49(18):2425-2435.
GREEN A C,OLSEN C M. Cutaneous squamous cell carcinoma:an epidemiological review[J]. Br J Dermatol,2017,177(2):373-381.
OGATA D,TSUCHIDA T. Systemic immunotherapy for advanced cutaneous squamous cell carcinoma[J]. Curr Treat Options Oncol,2019,20(4):30.
LEAL-ESTEBAN L C,FAJAS L. Cell cycle regulators in cancer cell metabolism[J]. Biochim Biophys Acta Mol Basis Dis,2020,1866(5):165715.
OBENG E. Apoptosis (programmed cell death) and its signals :a review[J]. Revista Brasleira De Biol,2021,81(4):1133-1143.
KETELUT-CARNEIRO N,FITZGERALD K A. Apoptosis,pyroptosis,and necroptosis-oh my! the many ways a cell can Die[J]. J Mol Biol,2022,434(4):167378.
BANERJEE S,BIEHL A,GADINA M,et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases:current and future prospects[J]. Drugs,2017,77(5):521-546.
XIN P,XU X Y,DENG C J,et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases[J]. Int Immunopharmacol,2020,80:106210.
MENGIE AYELE T,TILAHUN MUCHE Z,BEHAILE TEKLEMARIAM A,et al. Role of JAK2/STAT3 signaling pathway in the tumorigenesis,chemotherapy resistance,and treatment of solid tumors:a systemic review[J]. J Inflamm Res,2022,15:1349-1364.
TANG C,ZHAO C C,YI H,et al. Traditional Tibetan medicine in cancer therapy by targeting apoptosis pathways[J]. Front Pharmacol,2020,11:976.
BALACHANDRAN C,ARUN Y ,SANGEETHA B,et al. In vitro and in vivo anticancer activity of 2-acetyl-benzylamine isolated from Adhatoda vasica L. leaves[J]. Biomed Pharmacother,2017,93:796-806.
HAFEZI S,RAHMANI M. Targeting Bcl-2 in cancer: advances,challenges,and perspectives[J]. Cancers (Basel),2021,13(6):1292.